Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Trade group seeks more U.S. pressure on India over patent protection

02/07/2014 | 01:44pm EDT
A patient holds free medicine provided by the government at RGGGH in Chennai

(Reuters) - The U.S. Chamber of Commerce on Friday called on the government to ratchet up pressure on India over intellectual property rights, in a move that could help prevent Indian companies from producing cheap generic versions of medicines still under patent protection.

In a submission to the Office of U.S. Trade Representative (USTR), the Chamber of Commerce requested that India be classified a Priority Foreign Country, a tag given to the worst offenders when it comes to protecting intellectual property, and one that could trigger trade sanctions.

India is currently on the U.S. government's Priority Watch List for countries whose practices on protecting intellectual property Washington believes should be monitored closely.

In its new submission, the Global Intellectual Property Center (GIPC) of the Chamber of Commerce said: "We highlight India as a country with particular challenges with respect to intellectual property protections."

"Because India has not shown a record of engagement on these issues and the environment has deteriorated significantly since last year, we are now recommending that India be designated a Priority Foreign Country," it said.

The perspective from India is that many patented drugs are too costly for most people. The government in New Delhi is pushing to increase access to life-saving treatments where only 15 percent of 1.2 billion people are covered by health insurance.

India received the lowest score in the trade group's IP Index released last week, performing poorly in all six of its rating categories - patents, copyrights, trademarks, trade secrets and market access, enforcement, and membership and ratification of international treaties.

The U.S. industry trade group for drugmakers, Pharmaceutical Research and Manufacturers of America (PhRMA), is scheduled to detail its concerns about India and other countries to the U.S. Trade Representative later on Friday.

The recommendations are for a document known as a Special 301 Report, which is prepared annually by the Office of the United States Trade Representative.

It is quite possible that PhRMA will also recommend placing India on the worst offenders' list based on concerns of many of its member companies.

The industry push for a tougher line on India was first revealed in a Reuters report on Thursday, although at least one member, British drugmaker GlaxoSmithKline (>> GlaxoSmithKline plc), has called for constructive engagement with Indian officials rather than a harder line stance.

Calls for turning up the pressure on India come at a time when an Indian government committee is reviewing patented medicines sold by foreign drugmakers to see if so-called compulsory licenses, which in effect break exclusivity rights, can be issued for some of them in an effort to bring down costs, two senior government officials told Reuters.

The drugs being considered for such patent-breaking licenses are used for treating cancer, diabetes, hepatitis and HIV, said the sources, declining to give details. No timeline has been given for completion of the India review process.

(Reporting by Bill Berkrot; Editing by Stephen Powell)

By Bill Berkrot

ę Reuters 2014
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.47% 8253 Delayed Quote.13.22%
BRISTOL-MYERS SQUIBB COMPANY -0.30% 67.49 Delayed Quote.9.12%
ELI LILLY AND COMPANY 0.15% 243.58 Delayed Quote.44.05%
GLAXOSMITHKLINE PLC -0.04% 1399.2 Delayed Quote.4.31%
MERCK & CO., INC. 0.79% 77.85 Delayed Quote.-5.57%
ROCHE HOLDING AG 0.00% 344.55 Delayed Quote.11.50%
07/26GLAXOSMITHKLINE PHARMACEUTICALS' : Consolidated Net Profit Climbs in Fiscal Q1
07/26GLAXOSMITHKLINE : Shingles Vaccine Gets Expanded US Nod For Immunocompromised Ad..
07/26BIONTECH : Plans Development of First mRNA-Based Malaria Vaccine
07/26GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
07/26GLAXOSMITHKLINE : BioNTech aims to develop mRNA-based malaria vaccine
07/26GLAXOSMITHKLINE : Wins US FDA Approval for Shingrix for Shingles Prevention in I..
07/26ASTRAZENECA : BioNTech aims to develop mRNA-based malaria vaccine
07/26GLAXOSMITHKLINE : Shingrix approved in the US for prevention of shingles in immu..
07/26GlaxoSmithKline plc Announces US Food and Drug Administration Approval for Sh..
07/26GlaxoSmithKline Gets FDA Approval for Shingles Vaccine
More news
Sales 2021 33 019 M 45 826 M 45 826 M
Net income 2021 3 385 M 4 698 M 4 698 M
Net Debt 2021 21 463 M 29 789 M 29 789 M
P/E ratio 2021 20,4x
Yield 2021 5,72%
Capitalization 70 017 M 96 771 M 97 177 M
EV / Sales 2021 2,77x
EV / Sales 2022 2,59x
Nbr of Employees 94 066
Free-Float 92,2%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 13,99 GBX
Average target price 1 518,63 GBX
Spread / Average Target 10 754%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954